Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03345082 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A Phase 2 study, sponsored by Opthea Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT03345082: Completed Phase 2 study, sponsored by Opthea Limited.
NCT03345082 is a Phase 2 study that has completed, run by Opthea Limited. The registered enrollment target is 366 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (175% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03345082, a Phase 2 study, has completed, sponsored by Opthea Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
Interventions
- BIOLOGICAL ranibizumab
- BIOLOGICAL OPT-302
- OTHER sham intravitreal injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2019-05-14 |
| Phase | Phase 2 |
What the finished NCT03345082 record still lists
NCT03345082 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (175% higher).
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT03345082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03345082 about?
NCT03345082 is a clinical study titled "A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD". A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
What is the current status of trial NCT03345082?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2017-11-06. Estimated completion is 2019-05-14.
What interventions are being tested in trial NCT03345082?
The interventions under investigation include: ranibizumab (BIOLOGICAL), OPT-302 (BIOLOGICAL), sham intravitreal injection (OTHER).
Who is sponsoring clinical trial NCT03345082?
This trial is sponsored by Opthea Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03345082's enrollment target sits among peer trials
366 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI